CN1289499C - 吡嗪并(氮杂)吲哚衍生物 - Google Patents

吡嗪并(氮杂)吲哚衍生物 Download PDF

Info

Publication number
CN1289499C
CN1289499C CNB008031398A CN00803139A CN1289499C CN 1289499 C CN1289499 C CN 1289499C CN B008031398 A CNB008031398 A CN B008031398A CN 00803139 A CN00803139 A CN 00803139A CN 1289499 C CN1289499 C CN 1289499C
Authority
CN
China
Prior art keywords
hydrogen
chloro
pharmaceutical composition
halogen
indole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008031398A
Other languages
English (en)
Chinese (zh)
Other versions
CN1337963A (zh
Inventor
D·R·亚当斯
J·M·本特利
J·戴维森
M·A·J·敦克顿
R·H·P·波尔特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand UK Research Ltd
Original Assignee
Vernalis Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Research Ltd filed Critical Vernalis Research Ltd
Publication of CN1337963A publication Critical patent/CN1337963A/zh
Application granted granted Critical
Publication of CN1289499C publication Critical patent/CN1289499C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
CNB008031398A 1999-01-29 2000-01-28 吡嗪并(氮杂)吲哚衍生物 Expired - Fee Related CN1289499C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9902047.1A GB9902047D0 (en) 1999-01-29 1999-01-29 Chemical compounds XI
GB9902047.1 1999-01-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB2006100710947A Division CN100418968C (zh) 1999-01-29 2000-01-28 吡嗪并(氮杂)吲哚衍生物

Publications (2)

Publication Number Publication Date
CN1337963A CN1337963A (zh) 2002-02-27
CN1289499C true CN1289499C (zh) 2006-12-13

Family

ID=10846774

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB008031398A Expired - Fee Related CN1289499C (zh) 1999-01-29 2000-01-28 吡嗪并(氮杂)吲哚衍生物
CNB2006100710947A Expired - Fee Related CN100418968C (zh) 1999-01-29 2000-01-28 吡嗪并(氮杂)吲哚衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB2006100710947A Expired - Fee Related CN100418968C (zh) 1999-01-29 2000-01-28 吡嗪并(氮杂)吲哚衍生物

Country Status (18)

Country Link
US (4) US6800627B1 (https=)
EP (1) EP1147110B1 (https=)
JP (1) JP2002535408A (https=)
KR (1) KR100633375B1 (https=)
CN (2) CN1289499C (https=)
AT (1) ATE239731T1 (https=)
AU (1) AU758685B2 (https=)
BR (1) BR0008979A (https=)
CA (1) CA2359034A1 (https=)
DE (1) DE60002554T2 (https=)
DK (1) DK1147110T3 (https=)
ES (1) ES2199132T3 (https=)
GB (1) GB9902047D0 (https=)
MX (1) MXPA01007643A (https=)
PT (1) PT1147110E (https=)
TR (1) TR200102161T2 (https=)
WO (1) WO2000044753A1 (https=)
ZA (1) ZA200106202B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
FR2799757B1 (fr) * 1999-10-15 2001-12-14 Adir Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4180365B2 (ja) 2000-07-31 2008-11-12 エフ．ホフマン−ラ ロシュ アーゲー ピペラジン誘導体
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
NZ525699A (en) 2000-11-20 2005-03-24 Biovitrum Ab Piperazinylpyrazines compounds as antagonists of serotonin 5-HT2 receptor
EP1343768A1 (en) * 2000-12-20 2003-09-17 Bristol-Myers Squibb Pharma Company Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
AU2002259312B2 (en) 2001-06-01 2007-01-04 Alcon, Inc. Novel arylaminopropane analogues and their use for the treatment of glaucoma
EP1392658A4 (en) 2001-06-01 2004-10-13 Alcon Inc NOVEL FUSED INDAZOLES AND INDOLES AND THEIR USE IN THE TREATMENT OF GLAUCOMES
EP1392292B1 (en) 2001-06-01 2006-03-01 Alcon, Inc. Pyranoindazoles and their use for the treatment of glaucoma
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
GB0202015D0 (en) 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
JP4460450B2 (ja) 2002-06-19 2010-05-12 ビオヴィトルム・アクチボラゲット（プブリクト） 新規化合物、その使用および製造法
CA2506204A1 (en) 2002-12-13 2004-07-01 Alcon, Inc. Novel benzopyran analogs and their use for the treatment of glaucoma
NZ543482A (en) * 2003-05-21 2009-02-28 Prosidion Ltd Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
US7476687B2 (en) 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
WO2005058911A2 (en) 2003-12-15 2005-06-30 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
WO2006062839A1 (en) 2004-12-08 2006-06-15 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
CN101171252B (zh) * 2005-05-03 2011-06-01 霍夫曼-拉罗奇有限公司 作为5-ht2配体的四环氮杂吡嗪并二氢吲哚类化合物
UA95788C2 (en) 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
ES2344077T3 (es) 2005-12-16 2010-08-17 F.Hoffmann-La Roche Ag Derivados de pirrolo(2,3-b)piridina como moduladores del receptor h3.
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
EP2789338A3 (en) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
EP2254886B1 (en) 2008-03-28 2016-05-25 Nerviano Medical Sciences S.r.l. 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
MX363662B (es) * 2012-10-08 2019-03-27 Centro De Investig Y De Estudios Avanzados Del I P N Star Métodos para incrementar la sensibilidad a insulina mediante agonistas de receptores serotonérgicos 5-ht2.
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
JP6217561B2 (ja) * 2014-08-21 2017-10-25 信越化学工業株式会社 新規オニウム塩化合物及びレジスト組成物並びにパターン形成方法
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
WO2021086038A1 (ko) * 2019-10-31 2021-05-06 홀로스메딕 주식회사 신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE792724A (fr) * 1971-12-16 1973-06-14 Merck Patent Gmbh Derives de pyrazinoindole et leur procede de preparation
EP0572863A1 (de) * 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag ZNS Pyrazinoindole
TW334423B (en) 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
US5854245A (en) * 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
GB9819033D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
GB9819019D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
GB9819032D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds IV
GB9918962D0 (en) * 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxii

Also Published As

Publication number Publication date
US20040039200A1 (en) 2004-02-26
GB9902047D0 (en) 1999-03-17
TR200102161T2 (tr) 2002-05-21
EP1147110B1 (en) 2003-05-07
ES2199132T3 (es) 2004-02-16
MXPA01007643A (es) 2003-06-24
KR20010101873A (ko) 2001-11-15
WO2000044753A1 (en) 2000-08-03
ATE239731T1 (de) 2003-05-15
PT1147110E (pt) 2003-09-30
US20060160816A1 (en) 2006-07-20
ZA200106202B (en) 2002-07-29
JP2002535408A (ja) 2002-10-22
DE60002554T2 (de) 2004-03-25
DK1147110T3 (da) 2003-09-01
BR0008979A (pt) 2002-02-05
US20040092525A1 (en) 2004-05-13
US7145009B2 (en) 2006-12-05
US6800627B1 (en) 2004-10-05
AU2119600A (en) 2000-08-18
CN1337963A (zh) 2002-02-27
CA2359034A1 (en) 2000-08-03
KR100633375B1 (ko) 2006-10-16
AU758685B2 (en) 2003-03-27
CN100418968C (zh) 2008-09-17
DE60002554D1 (de) 2003-06-12
EP1147110A1 (en) 2001-10-24
CN1837207A (zh) 2006-09-27

Similar Documents

Publication Publication Date Title
CN1289499C (zh) 吡嗪并(氮杂)吲哚衍生物
CN1165537C (zh) 作为5-ht2c兴奋剂的吡咯并吲哚、吡啶并吲哚和氮杂�并吲哚
CN1277828C (zh) 哌嗪衍生物
CN1187330C (zh) 吲哚衍生物、制备它们的方法、含有它们的药用组合物和它们的医疗应用
CN1255403C (zh) 用作磷酸二酯酶抑制剂的β－咔啉衍生物
CN1128788C (zh) 苄基(亚苄基)－内酰胺衍生物,它们的制备以及作为5－ht1a和/或5－ht1d受体的选择性拮抗剂(激动剂)的用途
CN1290847C (zh) 氮杂－芳基哌嗪类化合物
CN1308311C (zh) 新型吡啶－和喹啉－衍生物
CN1250549C (zh) 吲哚衍生物及其作为5－ht2b和5－ht2c受体配体的应用
CN1061341C (zh) 1－氨基乙基吲哚衍生物
CN1167681C (zh) 稠合二氢吲哚衍生物及其作为5ht特别是5ht2c受体配体的用途
CN1273469C (zh) 作为保胎用催产素受体拮抗剂的三环二氮杂䓬
CN1668590A (zh) 用作5－羟色胺－6配体的1－杂环基烷基－3－磺酰基－吲哚或－吲唑衍生物
CN1527816A (zh) 新的具有5-ht6受体亲和性的吲哚衍生物
CN1245405C (zh) 哌嗪衍生物
CN1072219C (zh) 二氮杂䓬酮、其生产和用途
CN1713910A (zh) 作为p38激酶抑制剂的氮杂吲哚衍生物
CN1454211A (zh) 作为Xa因子抑制剂的含氮杂双环化合物
CN87103504A (zh) 杂环羧酰胺
CN1771244A (zh) 作为5－羟色胺－6配体的杂环－3－磺酰基吲唑
CN1701068A (zh) 新颖的化合物和它们的用途
CN1606553A (zh) 催产素激动药
CN1929737A (zh) Hiv整合酶抑制剂
CN1503797A (zh) 吡啶并嘧啶或二氮杂萘衍生物
CN1285594C (zh) 催产素兴奋剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CI01 Publication of corrected invention patent application

Correction item: Inventor (fourth inventor)

Correct: Duncton Matthew Alexander Jame

False: M, A, J, London, Morton

Number: 9

Volume: 18

CI02 Correction of invention patent application

Correction item: Inventor (fourth inventor)

Correct: Duncton Matthew Alexander Jame

False: M, A, J, London, Morton

Number: 9

Page: The title page

Volume: 18

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR ( THE FOURTH INVENTOR ); FROM: M A J DUNWU DAYTON TO: DUNCTON MATTHEW ALEXANDER JAME

ERR Gazette correction

Free format text: CORRECT: INVENTOR ( THE FOURTH INVENTOR ); FROM: M A J DUNWU DAYTON TO: DUNCTON MATTHEW ALEXANDER JAME

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20061213

Termination date: 20100301